Affimed (NASDAQ:AFMD) Given Overweight Rating at Cantor Fitzgerald

Affimed (NASDAQ:AFMDGet Rating)‘s stock had its “overweight” rating reaffirmed by stock analysts at Cantor Fitzgerald in a report released on Wednesday, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Affimed’s FY2022 earnings at ($0.63) EPS and FY2023 earnings at ($0.88) EPS.

A number of other equities research analysts have also recently weighed in on the stock. Wells Fargo & Company reiterated an “overweight” rating on shares of Affimed in a research report on Thursday, August 18th. StockNews.com upgraded shares of Affimed from a “sell” rating to a “hold” rating in a report on Monday, August 22nd. Finally, SVB Leerink dropped their price objective on shares of Affimed from $10.00 to $9.00 and set an “outperform” rating for the company in a report on Thursday, June 23rd. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Affimed Price Performance

Shares of AFMD opened at $2.03 on Wednesday. Affimed has a 1-year low of $1.93 and a 1-year high of $7.35. The stock has a market cap of $250.54 million, a PE ratio of -2.94 and a beta of 2.32. The firm has a 50-day simple moving average of $2.83 and a two-hundred day simple moving average of $3.30. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.90 and a quick ratio of 4.89.

Affimed (NASDAQ:AFMDGet Rating) last announced its quarterly earnings results on Thursday, August 11th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. Affimed had a negative net margin of 232.11% and a negative return on equity of 54.94%. The business had revenue of $7.78 million during the quarter, compared to analysts’ expectations of $8.12 million. As a group, analysts forecast that Affimed will post -0.68 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in AFMD. Point72 Asset Management L.P. lifted its stake in Affimed by 93.6% in the fourth quarter. Point72 Asset Management L.P. now owns 11,855,151 shares of the biopharmaceutical company’s stock worth $65,440,000 after acquiring an additional 5,732,500 shares during the last quarter. Woodline Partners LP purchased a new position in Affimed in the second quarter worth approximately $6,953,000. Bain Capital Public Equity Management II LLC lifted its stake in Affimed by 118.8% in the second quarter. Bain Capital Public Equity Management II LLC now owns 1,274,153 shares of the biopharmaceutical company’s stock worth $3,529,000 after acquiring an additional 691,817 shares during the last quarter. Platinum Investment Management Ltd. purchased a new position in Affimed in the second quarter worth approximately $1,604,000. Finally, Walleye Capital LLC purchased a new position in Affimed in the second quarter worth approximately $1,092,000. Hedge funds and other institutional investors own 71.08% of the company’s stock.

About Affimed

(Get Rating)

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma.

Featured Stories

Analyst Recommendations for Affimed (NASDAQ:AFMD)

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.